Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder.

OBJECTIVE: Impaired cognition is a hallmark of schizophrenia spectrum disorders, including schizotypal personality disorder, and it is the best predictor of functional outcome. Cognitive remediation therapy has demonstrated efficacy for improving cognition, augmenting other rehabilitation efforts in schizophrenia, and effecting gains in real-world functioning. Pharmacological augmentation of cognitive remediation has been attempted, but the effects of augmentation on combined therapies, such as cognitive remediation and social skills training, have not been studied. METHODS: Twenty-eight participants with schizotypal personality disorder enrolled in an 8-week, randomized, double-blind, placebo-controlled trial of guanfacine plus cognitive remediation and social skills training (15 guanfacine, 13 placebo). Cognition was assessed with the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB), social cognition with the Movie for the Assessment of Social Cognition (MASC), and functional capacity with the University of California San Diego Performance-Based Skills Assessment (UPSA). RESULTS: A statistically significant pre- versus posttreatment effect was observed for MCCB speed of processing, verbal learning, and visual learning and UPSA total score. A significant time-by-medication (guanfacine, placebo) interaction was observed for MCCB reasoning and problem solving and UPSA total score; the time-by-treatment interaction approached significance for MASC hypomentalizing errors. CONCLUSIONS: Both guanfacine and cognitive remediation plus social skills training were well tolerated, with no side effects or dropouts. Participants treated with cognitive remediation, social skills training, and guanfacine demonstrated statistically significant improvements in reasoning and problem solving, as well as in functional capacity and possibly social cognition, compared with those treated with cognitive remediation, social skills training, and placebo. Cognitive remediation plus social skills training may be an appropriate intervention for individuals with schizotypal personality disorder, and guanfacine appears to be a promising pharmaceutical augmentation to this psychosocial intervention.

[1]  J. Quezada,et al.  Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome , 2018, CNS Drugs.

[2]  Philip D. Harvey,et al.  Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia , 2017, Front. Psychiatry.

[3]  Philip D. Harvey,et al.  Placebo Response and Practice Effects in Schizophrenia Cognition Trials , 2017, JAMA psychiatry.

[4]  T L Patterson,et al.  UCSD Performance-Based Skills Assessment , 2016 .

[5]  P. Hammerness,et al.  Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. , 2016, JAMA.

[6]  F. López-Muñoz,et al.  Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd). , 2016, Actas espanolas de psiquiatria.

[7]  K. J. Carter,et al.  Treatment options for the management of pervasive developmental disorders , 2016, International journal of psychiatry in medicine.

[8]  Philip D. Harvey,et al.  Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity , 2015, Schizophrenia Research.

[9]  Susan M. Kaiser,et al.  Cognitive Enhancement Treatment for People With Mental Illness Who Do Not Respond to Supported Employment: A Randomized Controlled Trial. , 2015, The American journal of psychiatry.

[10]  I. Melle,et al.  Theory of mind in schizophrenia: Error types and associations with symptoms , 2015, Schizophrenia Research.

[11]  M. Keshavan,et al.  A pilot study of cognitive training in clinical high risk for psychosis: Initial evidence of cognitive benefit , 2014, Schizophrenia Research.

[12]  Philip D. Harvey,et al.  Vocational functioning in schizotypal and paranoid personality disorders , 2013, Psychiatry Research.

[13]  Danielle A Schlosser,et al.  Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia. , 2013, Annual review of clinical psychology.

[14]  Philip D. Harvey,et al.  Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder , 2013, Schizophrenia Research.

[15]  Vyv Huddy,et al.  A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes , 2012 .

[16]  Philip D. Harvey,et al.  Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: Differential sensitivity of clinical neuropsychological and experimental information processing tests , 2008, Schizophrenia Research.

[17]  Larry J. Seidman,et al.  NEUROPSYCHOLOGY OF THE PRODROME TO PSYCHOSIS IN THE NAPLS CONSORTIUM: RELATIONSHIP TO FAMILY HISTORY AND CONVERSION TO PSYCHOSIS , 2008, Schizophrenia Research.

[18]  Philip D. Harvey,et al.  Predicting Schizophrenia Patients’ Real-World Behavior with Specific Neuropsychological and Functional Capacity Measures , 2008, Biological Psychiatry.

[19]  Michael F. Green,et al.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. , 2008, The American journal of psychiatry.

[20]  E. Twamley,et al.  A meta-analysis of cognitive remediation in schizophrenia. , 2007, The American journal of psychiatry.

[21]  Philip D. Harvey,et al.  The Effects of Guanfacine on Context Processing Abnormalities in Schizotypal Personality Disorder , 2007, Biological Psychiatry.

[22]  Philip D. Harvey,et al.  Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: Evidence for specificity of relationships? , 2007, Schizophrenia Research.

[23]  S. Eack,et al.  Durability and mechanism of effects of cognitive enhancement therapy. , 2006, Psychiatric services.

[24]  Michael F. Green,et al.  Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. , 2006, The Journal of clinical psychiatry.

[25]  Jan K. Woike,et al.  Introducing MASC: A Movie for the Assessment of Social Cognition , 2006, Journal of autism and developmental disorders.

[26]  Robert K. Heaton,et al.  Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. , 2006, The American journal of psychiatry.

[27]  Philip D. Harvey,et al.  Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. , 2005, Archives of general psychiatry.

[28]  L. Siever,et al.  Neuropsychological performance in schizotypal personality disorder: importance of working memory. , 2005, The American journal of psychiatry.

[29]  Josef Parnas,et al.  Premorbid neurocognitive functioning in schizophrenia spectrum disorder. , 2005, Schizophrenia bulletin.

[30]  E. Chen,et al.  A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients , 2005, Schizophrenia Research.

[31]  Philip D. Harvey,et al.  Cognition in schizophrenia: impairments, determinants, and functional importance. , 2005, The Psychiatric clinics of North America.

[32]  R. Heinrichs.  The primacy of cognition in schizophrenia. , 2005, The American psychologist.

[33]  Philip D. Harvey,et al.  Context-processing deficits in schizotypal personality disorder. , 2004, Journal of abnormal psychology.

[34]  Philip D. Harvey,et al.  Guanfacine Treatment of Cognitive Impairment in Schizophrenia , 2001, Neuropsychopharmacology.

[35]  B. Mowry,et al.  Structured interview for DSM-IV personality: SIDP-IV , 1998 .

[36]  D. Stuss,et al.  The effects of focal anterior and posterior brain lesions on verbal fluency , 1998, Journal of the International Neuropsychological Society.

[37]  R. Keefe,et al.  Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay , 1997, Schizophrenia Research.

[38]  Edward E. Smith,et al.  A Parametric Study of Prefrontal Cortex Involvement in Human Working Memory , 1996, NeuroImage.

[39]  Douglas C. Noll,et al.  Activation of Prefrontal Cortex in Children during a Nonspatial Working Memory Task with Functional MRI , 1995, NeuroImage.

[40]  D. Gronwall.  Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion , 1977, Perceptual and motor skills.

[41]  Jason M. White,et al.  Alpha2-adrenergic agonists for the management of opioid withdrawal. , 2014, The Cochrane database of systematic reviews.

[42]  M. First,et al.  Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research version (SCID-I RV) , 2002 .